Salarius shares surge 18.32% intraday after announcing name change to Decoy Therapeutics and AI-powered peptide conjugate drug development for antiviral therapies.
ByAinvest
Wednesday, Jan 7, 2026 10:12 am ET1min read
SLRX--
Salarius surged 18.32% in intraday trading, with the company announcing a name change to Decoy Therapeutics and a stock ticker change to DCOY, reflecting its focus on developing novel peptide conjugate therapies using an AI-powered platform. The company's antiviral projects targeting coronaviruses and multi-virus threats have attracted attention from global health organizations like BARDA, and it unveiled a 2026 capital-efficient plan to advance clinical trials, expand its R&D pipeline, and seek partnerships.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet